Trusted by clinicians worldwide. Supporting 2.5 million patient visits weekly.
Warning: Clinical review pending: not for clinical use
Before you score. Validated in non-valvular AF only. Do not apply to rheumatic AF, mechanical valves, or mitral stenosis.
Congestive heart failure
Signs/symptoms of HF or reduced LVEF
Hypertension
BP >140/90 on ≥2 occasions or on treatment
Age
Diabetes mellitus
Fasting glucose >125 mg/dL or on treatment
Stroke, TIA, or thromboembolism
Prior history: highest single risk factor (S₂)
Vascular disease
Prior MI, peripheral artery disease, or aortic plaque
Sex category
Female sex adds 1 point (Sc)
For clinical decision support only. Always integrate with full clinical assessment, local guidelines, and patient preferences.
The CHA₂DS₂-VASc score is a point-based risk stratification tool used in non-valvular atrial fibrillation to estimate the annual risk of ischaemic stroke or systemic thromboembolism, guiding anticoagulation decisions. Calculate below:
Every summary carries citations with verbatim excerpts from the source, so you can open it, read it in context and confirm it says what the answer claims. What surfaces are decided by clinical quality, the governed alternative to pasting a clinical question into a general AI chatbot and hoping the answer holds.
Heidi Evidence draws on sources clinicians already trust, from Elsevier and DynaMed to MIMS Australia, and your organization can layer in its own regional pathways, policies, and formularies.
Heidi is the first in its field to hold ISO 42001 certification for AI management. Since Evidence is designed as a reference tool, the clinical call (and the responsibility for it) stays with you.
Evidence draws on the patient visit and its context, so the specifics travel with the question instead of being left behind. When a calculation is involved, the logic sits alongside the result, so you can see how it was reached and confirm it yourself rather than trust a black box.
Making that connection between the patient and the GP, like a puzzle fitting together.
Deborah Hawthorne
Evidence draws on what's already been discussed in the session and surfaces relevant context: clinical patterns, research, decision-support prompts.
Dr. Jane McNae
Clinicians at Connect2Care
Medical knowledge only. Not for autonomous decision making. Check sources and use your clinical judgement.
Australian practice follows the sexless CHA₂DS₂-VA variant, where a score of 0 means anticoagulation is not recommended, a score of 1 means it should be considered, and a score of 2 or more means it is recommended.
International AHA/ACC/HRS practice retains the sex-modified score and recommends oral anticoagulation for men with a score of 2 or more and women with 3 or more, with intermediate scores (men at 1, women at 2) treated as reasonable rather than mandatory.
When anticoagulation is indicated, direct oral anticoagulants are preferred over warfarin for non-valvular AF. Because risk is dynamic, reassess the score at least annually so patients who accrue new risk factors are not missed.